JP2024511451A - 選択的アンジオテンシンｉｉ受容体リガンド - Google Patents

選択的アンジオテンシンｉｉ受容体リガンド Download PDF

Info

Publication number
JP2024511451A
JP2024511451A JP2023558498A JP2023558498A JP2024511451A JP 2024511451 A JP2024511451 A JP 2024511451A JP 2023558498 A JP2023558498 A JP 2023558498A JP 2023558498 A JP2023558498 A JP 2023558498A JP 2024511451 A JP2024511451 A JP 2024511451A
Authority
JP
Japan
Prior art keywords
compound
formula
alkyl
compounds
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511451A5 (https=
JPWO2022200787A5 (https=
Inventor
フェックス，トマス
オルソン，ベンクト
ハルベルグ，アンダース
ラーヘド，マッツ
Original Assignee
ヴィコール ファルマ アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィコール ファルマ アーベー filed Critical ヴィコール ファルマ アーベー
Publication of JP2024511451A publication Critical patent/JP2024511451A/ja
Publication of JP2024511451A5 publication Critical patent/JP2024511451A5/ja
Publication of JPWO2022200787A5 publication Critical patent/JPWO2022200787A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023558498A 2021-03-23 2022-03-23 選択的アンジオテンシンｉｉ受容体リガンド Pending JP2024511451A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2104033.2A GB202104033D0 (en) 2021-03-23 2021-03-23 New compounds
GB2104033.2 2021-03-23
PCT/GB2022/050727 WO2022200787A1 (en) 2021-03-23 2022-03-23 Selective angiotensin ii receptor ligands

Publications (3)

Publication Number Publication Date
JP2024511451A true JP2024511451A (ja) 2024-03-13
JP2024511451A5 JP2024511451A5 (https=) 2025-03-31
JPWO2022200787A5 JPWO2022200787A5 (https=) 2025-03-31

Family

ID=75689748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558498A Pending JP2024511451A (ja) 2021-03-23 2022-03-23 選択的アンジオテンシンｉｉ受容体リガンド

Country Status (7)

Country Link
US (1) US20240197685A1 (https=)
EP (1) EP4313977A1 (https=)
JP (1) JP2024511451A (https=)
CN (1) CN117242071A (https=)
CA (1) CA3212188A1 (https=)
GB (1) GB202104033D0 (https=)
WO (1) WO2022200787A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20230600A3 (en) 2022-12-22 2025-09-24 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064414A1 (en) * 2002-01-29 2003-08-07 Vicore Pharma Ab. Tricyclic compounds useful as angiotensin ii agonists
JP2004533457A (ja) * 2001-05-31 2004-11-04 ヴィコール・ファルマ・アーベー アンギオテンシンｉｉアゴニストとして有用な三環式化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
CA2449150C (en) 2001-05-31 2011-07-12 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
WO2004046141A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
BR112017012337A2 (pt) 2014-12-12 2018-02-27 Vicore Pharma Ab Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação.
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
CN107405406A (zh) 2015-03-02 2017-11-28 维科尔药物公司 用于治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
AR108906A1 (es) * 2016-06-29 2018-10-10 Bristol Myers Squibb Co Heterociclos de biarilmetilo
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
GB201913603D0 (en) * 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
KR20230004501A (ko) * 2020-03-19 2023-01-06 바이코어 파마 아베 안지오텐신 ⅱ와 관련된 질병, 장애, 또는 병태의 치료 및/또는 예방에 유용한 신규 화합물
GB202013721D0 (en) * 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533457A (ja) * 2001-05-31 2004-11-04 ヴィコール・ファルマ・アーベー アンギオテンシンｉｉアゴニストとして有用な三環式化合物
WO2003064414A1 (en) * 2002-01-29 2003-08-07 Vicore Pharma Ab. Tricyclic compounds useful as angiotensin ii agonists

Also Published As

Publication number Publication date
WO2022200787A1 (en) 2022-09-29
US20240197685A1 (en) 2024-06-20
CN117242071A (zh) 2023-12-15
CA3212188A1 (en) 2022-09-29
GB202104033D0 (en) 2021-05-05
EP4313977A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
JP7771049B2 (ja) 新化合物
US12441718B2 (en) Selective angiotensin II compounds
JP2023539614A (ja) アンジオテンシンｉｉに関連する疾患の治療に使用するための新規化合物
JP7773988B2 (ja) アンジオテンシンｉｉに関連する疾患の治療における使用のためのイミダゾリルチオフェンスルホニルカルバメート
JP2024511452A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
GB2605148A (en) New compounds
JP2024511451A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
JP2026502510A (ja) 選択的アンジオテンシンｉｉ化合物
JP2024511453A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
CN117222624A (zh) 选择性血管紧张素ii受体配体
CN117916229A (zh) 新型选择性血管紧张素ii化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250321

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313